PubRank

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Clinical Trial ID NCT00940225

PubWeight™ 33.80‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00940225

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2012 3.92
2 Targeted therapies for breast cancer. J Clin Invest 2011 2.22
3 The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2010 2.07
4 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
5 Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012 1.55
6 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
7 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
8 A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013 1.33
9 MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 2011 1.10
10 Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014 1.10
11 Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013 1.09
12 XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010 1.09
13 Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2011 1.01
14 Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol 2013 0.99
15 Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015 0.97
16 Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol 2014 0.94
17 Ovarian cancer: opportunity for targeted therapy. J Oncol 2011 0.90
18 Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther 2014 0.88
19 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
20 Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 2015 0.85
21 Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2012 0.85
22 MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015 0.84
23 The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res 2015 0.79
24 Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg 2012 0.78
25 Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J Transl Med 2016 0.78
26 MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res 2012 0.78
27 New horizons in melanoma treatment: targeting molecular pathways. Ochsner J 2010 0.76
28 Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat 2016 0.75
Next 100